Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2023
Same author

Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2022
Same author

Daratumumab-based therapies in transplant-ineligible patients with untreated multiple myeloma and hepatic dysfunction: A systematic review of subgroup analyses.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2021
Same author

Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series.

European journal of hospital pharmacy : science and practice·2021
Same author

Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: A systematic review and assessment of subgroup analyses.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2021
Same author

Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients.

European journal of haematology·2020

Related Experiment Video

Updated: Sep 29, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K

Belantamab mafodotin for relapsed or refractory multiple myeloma.

Manuel David Gil-Sierra1,2, Maria Del Pilar Briceño-Casado3

  • 1Pharmacy Department, Hospital Universitario Puerto Real, Ctra. N-IV Km. 665, 11510 Puerto Real, Cadiz, Spain.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|March 21, 2022
PubMed
Summary

Belantamab mafodotin shows promise for refractory multiple myeloma (MM), achieving objective responses in about 30% of patients. Comparative studies are needed to confirm its therapeutic positioning against other MM treatments.

Keywords:
Belantamab mafodotinantibodiesclinical decision-makingdrug evaluationmonoclonalmultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Related Experiment Videos

Last Updated: Sep 29, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.5K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.5K
Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Refractory multiple myeloma (MM) has limited treatment options and poor responses to existing therapies.
  • Newer agents offer hope for heavily pretreated MM patients.

Purpose of the Study:

  • To provide a comparative commentary on belantamab mafodotin versus other therapies for heavily pretreated relapsed or refractory MM.
  • To evaluate the evidence regarding efficacy, safety, and cost-effectiveness.

Main Methods:

  • Data extracted from pivotal clinical trials.
  • Comparative analysis of response rates, survival data, adverse events, and budgetary impact.

Main Results:

  • Belantamab mafodotin achieved an overall response rate of approximately 30%.
  • Specific adverse events include visual disturbances and kerathopathies; high-grade events were frequent.
  • Belantamab mafodotin suggested increased efficiency compared to chimeric antigen receptor T-cell therapies.
  • High budgetary impact noted for various treatments.

Conclusions:

  • Belantamab mafodotin and other novel regimens are promising for MM, particularly triple-class refractory patients.
  • Further comparative studies with larger sample sizes are essential for definitive therapeutic positioning.
  • Subgroup analyses for extramedullary disease and ISS stage III require thorough evaluation.